New Analysis from Phase 3 Clarity AD Study Reveals Health and Financial Benefits of Lecanemab

Published Date: 30 Mar 2023

At a willingness-to-pay threshold of $200,000 per QALY gained, the estimated annual cost of lecanemab is $35,678 and $37,351 from the perspective of payer and community, respectively.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Examines Office-Based Transperineal Prostate Biopsies Methodology.

2.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

3.

Is a $2,000 Whole-Body MRI Worth It?

4.

Surgery may not be necessary to treat invasive breast cancer

5.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot